TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alphamab Oncology ( (HK:9966) ) just unveiled an update.
Alphamab Oncology announced its interim results for the first half of 2025, reporting a significant increase in revenue and a return to profitability compared to the same period in 2024. The company achieved several milestones in its clinical trials, including the publication of results for phase II studies and the initiation of phase III trials for its promising cancer treatments. These advancements are expected to strengthen Alphamab’s position in the oncology market and potentially offer new treatment options for patients with HER2-positive and other types of cancer.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company focused on the development and commercialization of innovative biologics for the treatment of cancer. The company is engaged in advancing its drug pipeline with a focus on novel therapies for various types of cancer, including breast cancer, lung cancer, and ovarian cancer.
Average Trading Volume: 4,323,879
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.98B
For a thorough assessment of 9966 stock, go to TipRanks’ Stock Analysis page.